China (Mainland)
Premiumsupplier
- Product Details
Keywords
- 164656-23-9
- Sell high quality Dutasteride produced in China factory
- Dutasteride seller in China
Quick Details
- ProName: Dutasteride
- CasNo: 164656-23-9
- Molecular Formula: C27H30F6N2O2
- Appearance: white fine powder
- Application: Used for research and industrial manuf...
- DeliveryTime: Within7-10 days after receipt of your ...
- PackAge: As customer request
- Port: Qingdao,China
- ProductionCapacity: 100kg/Month Metric Ton/Day
- Purity: 98%min
- Storage: Store in a cool,dry place and keep awa...
- Transportation: Common products:Sea/Air/Courier Dange...
- LimitNum: 100 Metric Ton
Superiority
Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.
Details
Quick Details
Details
| Dutasteride Basic information |
| Clinical evaluation Application |
| Product Name: | Dutasteride |
| Synonyms: | (5alpha,17beta)-n-{2,5-bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-l-ene-17-carboxamide;DUTASTERIDE;GG-745, GI-198745,;5α,17β)-N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4- Aza -androst-1-ene-17-carboxamide;Duagen;(5a,17)-N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-carboxamide;Avodart;GI 198745 |
| CAS: | 164656-23-9 |
| MF: | C27H30F6N2O2 |
| MW: | 528.53 |
| EINECS: | |
| Product Categories: | Miscellaneous Biochemicals;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Steroid and Hormone;Hormone Drugs;API |
| Mol File: | 164656-23-9.mol |
|
|
|
| Dutasteride Chemical Properties |
| mp | 242-250°C |
| storage temp. | -20°C Freezer |
| Safety Information |
| Dutasteride Usage And Synthesis |
| Medicines to treat benign prostatic hyperplasia |
On October 9, 2002, dutasteride that was developed by GSK was approved by the US Food and Drug Administration for the use in the treatment of prostate enlargement. On June 19, 2008, GSK announced that the FDA approved for the combination of idutasteride and tamsulosin in the treatment of prostate hyperplasia. In China, on of two elderly men over the age of 60 have benign prostatic hyperplasia. It can cause urinary tract symptoms, including significant rise in frequency of urination, thin urine flow, bladder emptying difficulties, as well as nocturia. It even can cause serious complications, like acute urinary retention, reduce the patients’ life quality, and affect their social life. Dutasteride is the first and the only dual 5α reductase inhibitor to be used in the treatment of prostatic hyperplasia. It can improve urinary system symptom, reduce the onset of acute urinary retention and the risk of prostate surgery. Tamsulosin is α receptor blockers |
